Building Blocks

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>PB-22 is a synthetic cannabinoid, which can be classified as a CB1 receptor agonist. It is one of the many cannabinoids that have been created in an attempt to circumvent drug laws by creating compounds that are similar to those found in cannabis but have different chemical structures. PB-22 has shown to increase locomotor activity and stimulate the cb1 receptor in mice. Magnetic resonance spectroscopy (MRS) and assays were used to determine the binding affinity of PB-22 for the CB1 receptor. The MRS data showed that PB-22 bound with high affinity to the CB1 receptor and had a lower affinity for CB2 receptors. This suggests that PB-22 may be more potent than other synthetic cannabinoids, such as JWH-018 and CP 55,940, which bind better with CB2 receptors than CB1 receptors.<br>PB-22 is an analog of JWH-073 and has been shown to have a stronger effect on locomotor activity than JWH</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>2-Ethynyl-4-methylthiazole is a cell-based kinase inhibitor that binds to the ATP binding site on the enzyme and inhibits phosphorylation. It was shown to inhibit cell growth in vitro by interfering with the production of TGF-β, activin, and other growth factors. The inhibitory activity of 2-Ethynyl-4-methylthiazole is selective for receptor kinases and is not effective against alk5 kinase. This drug has been shown to be an inhibitor of cellular growth in vitro and may be useful for the treatment of cancer.</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Dichloroacetic acid methyl ester (DCA) is a metabolic disorder agent that belongs to the group of detergent compositions. It is an important intermediate in the synthesis of sodium salts and hiv infection inhibitors, such as hydrochloric acid and covalent linkages. DCA reacts with water molecules to form hydroxyl groups and then reacts with metal carbonyls to produce anhydrous sodium. This product also reacts with fatty acids to produce alcohol residue and can be used in the reaction solution. The product has a pyrazole ring with a hydroxyl group at one end and an alcohol residue at the other end.</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Naphthalene-2-carboximidamide is a benzamidine derivative that interacts with the active site of serine proteases. It was shown to have potent inhibitory potency against a number of proteinases, including urokinase-type plasminogen activator (uPA), matrix metalloproteinase-9 (MMP-9), and cathepsin G. The interaction of naphthalene-2-carboximidamide with uPA was specific and led to inhibition of its catalytic activity. Naphthalene-2-carboximidamide has been tested in clinical trials for the treatment of influenza.</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Chloromethyl cyclohexyl carbonate is a new acyclic nucleoside phosphonate that has been shown to have antiviral properties. It is active against HIV strains and inhibits the production of clotting factors. Chloromethyl cyclohexyl carbonate can be used as a drug substance for treating bowel disease, hepatitis, and cancer. It also modulates syncytial cells and heterocycles. Pharmacokinetic studies on chloromethyl cyclohexyl carbonate have shown that it has high bioavailability in the small intestine and liver after oral administration. It is metabolized by tyrosine kinase, which indicates that it may interfere with other drugs such as warfarin or phenytoin. Chloromethyl cyclohexyl carbonate has been found to be effective in treating gastritis and cancer in animal models.</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>1-N-(methylsulfonyl)-4-piperidinone is a compound that belongs to the group of secondary organic amines. It can be used as an intermediate in the synthesis of p-hydroxybenzoic acid and hydroxyl group compounds. 1-N-(methylsulfonyl)-4-piperidinone has been shown to inhibit protein synthesis in cultured cells by blocking the formation of aminoacyl-tRNA and preventing translocation of peptide chain from ribosomes to the site of peptide bond formation. This process is essential for the production of proteins, which are necessary for normal cell function. The inhibitory effect on protein synthesis was also observed when 1-N-(methylsulfonyl)-4-piperidinone was incubated with human erythrocytes, an enzyme isolated from calf thymus, and a monoclonal antibody (mAb). This mechanism is believed to be due</p>

<p>Versatile small molecule scaffold</p>

<p>3-Methyl-2-oxazolidone is an organic compound that is soluble in water and has a molecular weight of 114.3 g/mol. It can be produced by the reaction of methanol with oxalic acid, acetic acid, or malonic acid. 3-Methyl-2-oxazolidone is used as a solvent to dissolve other compounds and is used in the manufacture of sulfa drugs, hydrogen chloride, glycol ethers, and tetraphenylborates. 3-Methyl-2-oxazolidone has been shown to have electrochemical properties including proton conductivity and hydroxyl group oxidation. It also exhibits magnetic resonance properties due to its solute nature.</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>